BioSciences announced its board of directors has authorized a share repurchase program of up to an aggregate of $300M of the ...

April 22, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of ...

Pacira (PCRX) BioSciences announced the first patient has been dosed in the Phase 2 ASCEND study of PCRX-201 for the treatment of osteoarthritis, or OA, of the knee. PCRX-201 features an ...